NBIX - NEUROCRINE BIOSCIENCES INC

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 142.29

Open

$ 141.93

Bid

$ 142.25 x 200

Ask

$ 0.00 x 0

Day's Range

$ 140.46 - $ 142.85

52 Week Range

$ 89.04 - $ 148.37

Volume

641,937

Average Volume

Market Cap

14.74B

Beta (5Y Monthly)

$ 0.52

PE Ratio (TTM)

$ 39.87

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-01-2024	03-31-2024	10-Q
2	02-09-2024	12-31-2023	10-K
3	10-31-2023	09-30-2023	10-Q
4	08-01-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	02-09-2023	12-31-2022	10-K
7	11-01-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-11-2022	12-31-2021	10-K
11	11-01-2021	09-30-2021	10-Q
12	08-03-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	02-05-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-03-2020	06-30-2020	10-Q
17	05-06-2020	03-31-2020	10-Q
18	02-07-2020	12-31-2019	10-K
19	11-04-2019	09-30-2019	10-Q
20	07-29-2019	06-30-2019	10-Q
21	04-29-2019	03-31-2019	10-Q
22	02-08-2019	12-31-2018	10-K
23	11-05-2018	09-30-2018	10-Q
24	07-31-2018	06-30-2018	10-Q
25	04-30-2018	03-31-2018	10-Q
26	02-13-2018	12-31-2017	10-K
27	11-01-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-09-2017	03-31-2017	10-Q
30	02-14-2017	12-31-2016	10-K
31	11-02-2016	09-30-2016	10-Q
32	08-03-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	02-11-2016	12-31-2015	10-K
35	10-29-2015	09-30-2015	10-Q
36	07-29-2015	06-30-2015	10-Q
37	04-30-2015	03-31-2015	10-Q
38	02-09-2015	12-31-2014	10-K
39	11-04-2014	09-30-2014	10-Q
40	08-06-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Neurocrine Biosciences Presents Data At EC...
05/14/2024 12:43:34

- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents ...

Evercore ISI Group Initiates Coverage On N...
05/14/2024 09:16:08

Evercore ISI Group analyst Cory Kasimov initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform rating ...

Neurocrine Biosciences Presents CAHtalyst ...
05/09/2024 13:49:33

CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphy...

Nxera Pharma's Partner Neurocrine Bioscien...
05/09/2024 07:41:04

Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (("Ne...

Neurocrine Biosciences To Begin Initiation...
05/08/2024 12:38:26

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to eval...

Neurocrine Biosciences To Present Phase 3 ...
05/07/2024 12:38:33

CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Cli...

Citigroup Maintains Neutral on Neurocrine ...
05/03/2024 22:02:35

Citigroup analyst David Hoang maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from...

Canaccord Genuity Maintains Buy on Neurocr...
05/02/2024 19:19:48

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price tar...

Guggenheim Maintains Buy on Neurocrine Bio...
05/02/2024 18:23:52

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $...

Barclays Maintains Overweight on Neurocrin...
05/02/2024 18:00:28

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target f...

BMO Capital Maintains Market Perform on Ne...
05/02/2024 14:25:03

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and raises the price...

Oppenheimer Maintains Outperform on Neuroc...
05/02/2024 12:56:42

Oppenheimer analyst Jay Olson maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target f...

HC Wainwright & Co. Maintains Buy on Neuro...
05/02/2024 11:00:11

HC Wainwright & Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price t...

Needham Reiterates Hold on Neurocrine Bios...
05/02/2024 09:42:02

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.

Cracking The Code: Understanding Analyst R...
05/01/2024 17:00:48

Needham Reiterates Hold on Neurocrine Bios...
05/01/2024 15:48:17

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.

Neurocrine Biosciences Reiterates FY24 ING...
05/01/2024 11:10:19

Neurocrine Biosciences Q1 Adj $1.20 Beats ...
05/01/2024 11:06:13

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate o...

Neurocrine Biosciences Announces FDA Appro...
04/30/2024 21:46:06

Wells Fargo Upgrades Neurocrine Bioscience...
04/24/2024 14:14:12

Wells Fargo analyst Mohit Bansal upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Equal-Weight to Overweight and raises th...